Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 05, 2012

Regimen Shows Front-Line Promise in Advanced Pancreatobiliary Cancers

American Journal of Clinical Oncology

 

Additional Info

American Journal of Clinical Oncology
Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-Week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas
Am. J. Clin. Oncol 2012 Oct 01;35(5)411-417, AH Ko, AM Espinoza, KA Jones, et al

Further Reading